Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;46(2):192-9.
doi: 10.1038/bmt.2010.114. Epub 2010 May 24.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY

S Naik  1 , R Wong, S Arai, J Brown, G Laport, R Lowsky, D Miklos, J Shizuru, K Blume, R Negrin, L Johnston
Affiliations

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY

S Naik et al. Bone Marrow Transplant. 2011 Feb.

Abstract

Patients with high-risk or advanced myeloid malignancies have limited effective treatment options. These include high-dose therapy followed by allogeneic hematopoietic cell transplantation (HCT). We report a single-institution, long-term follow-up of 96 patients, median age 50 (range, 20-60) years, who received HLA-matched related HCT between 1992 and 2007. All patients were treated with a uniform preparatory regimen intended to enhance the widely used regimen of BU and CY that included: BU 16.0 mg/kg (days -8 to -5), etoposide 60 mg/kg (day -4), CY 60 mg/kg (day -2) with GVHD prophylaxis of CsA or FK506 and prednisone. Disease status at transplantation was high-risk AML (n=41), CML in second chronic phase or blast crisis (n=8), myelofibrosis and myeloproliferative disorders (n=8), and myelodysplasia (n=39). Thirty-six percent (n=35) of patients received BM whereas 64% (n=61) received G-CSF-mobilized PBPC. With a median follow-up of 5.6 years (range, 1.6-14.6 years) actuarial 5-year OS was 32% (95% CI 22-42) and 5-year EFS was 31% (95% CI 21-41). Relapse rate was 24% (95% CI 15-33) at 2 and 5 years. Nonrelapse mortality was 29% (95% CI 20-38) at day 100 and 38% (95% CI 29-47) at 1 year. Cumulative incidence of acute (grade II-IV) and extensive chronic GVHD was 27% (95% CI 18-36) and 29% (95% CI 18-40), respectively. There was no statistically significant difference in OS (31 vs 32%, P=0.89) or relapse rates (17 vs 28%, P=0.22) for recipients of BM vs PBPC, respectively. These results confirm that patients with high-risk or advanced myeloid malignancies can achieve long-term survival following myeloablative allogeneic HCT with aggressive conditioning.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(a) Cumulative incidence of acute GVHD receiving matched sibling donor allogeneic hematopoietic cell transplantation with BU/VP-16/CY myeloablative conditioning. (b) Cumulative incidence of chronic GVHD receiving matched sibling donor allogeneic hematopoietic cell transplantation with BU/VP-16/CY myeloablative conditioning.
Figure 2
Figure 2
(a) Kaplan–Meier estimates of OS and EFS in all 96 patients receiving matched sibling donor allogeneic hematopoietic cell transplantation with BU/VP-16/CY myeloablative conditioning. (b) Cumulative incidence of relapse in all 96 patients receiving matched sibling donor allogeneic hematopoietic cell transplantation with BU/VP-16/CY myeloablative conditioning. (c) Kaplan–Meier estimates of OS in different diagnostic categories. (d) Kaplan–Meier estimates of EFS in different diagnostic categories. Abbreviations: MF, myelofibrosis; MPD, myeloproliferative disorder; CML BC, CML in blast crisis; MDS, myelodysplastic syndromes; t-MDS/t-AML, therapy-related MDS/AML.
Figure 3
Figure 3
(a) Kaplan–Meier estimates of OS in all 96 patients receiving matched sibling donor allogeneic hematopoietic cell transplantation with BU/VP-16/CY myeloablative conditioning according to blast percentage (b). Kaplan-Meier estimates of EFS in all 96 patients receiving matched sibling donor allogeneic hematopoietic cell transplantation with BU/VP-16/CY myeloablative conditioning according to blast percentage.
See this image and copyright information in PMC

References

    1. Fung HC, Stein A, Slovak M, O’Donnell MR, Snyder DS, Cohen S, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant. 2003;9:766–771. - PubMed
    1. Appelbaum FR, Clift RA, Buckner CD, Stewart P, Storb R, Sullivan KM, et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse. Blood. 1983;61:949–953. - PubMed
    1. Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 1996;10:13–19. - PubMed
    1. Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005;35:965–970. - PubMed
    1. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11:108–114. - PubMed

MeSH terms